Baseline characteristics | Group I (n = 20) | Group 1I (n = 20) | p | |
---|---|---|---|---|
Age (mean ± SD) | 43.5 ± 7.4 | 43.8 ± 7.2 | 0.19 | |
Male: female (n, %) | 10(50):10(50) | 9 (45):11 (55) | 0.75 | |
Disease duration (mean ± SD) | 3.1 ± 1.6 | 3.0 ± 1.4 | 0.95 | |
RF titer (mean ± SD) | 101.2 ± 76.2 | 99.6 ± 73.1 | 0.65 | |
Viral load (X106) (mean ± SD) | 7.04 ± 8.02 | 6.76 ± 7.47 | 0.16 | |
ESR 1st hour | 52.2 ± 19.0 | 52.0 ± 16.7 | 0.78 | |
NRS for pain (mean ± SD) | 6.3 ± 2.9 | 6.2 ± 3.1 | 0.64 | |
TJC (mean ± SD) | 9.8 ± 9.4 | 10.2 ± 10.6 | 0.07 | |
SJC (mean ± SD) | 7.3 ± 7.9 | 7.3 ± 8.2 | 0.98 | |
Morning stiffness (MS) (mean ± SD) | 68.9 ± 22.7 | 68.5 ± 26.5 | 0.19 | |
GSUS synovitis score (mean ± SD) | 1.8 ± 0.8 | 1.9 ± 0.8 | 0.41 | |
PDUS score (mean ± SD) | 0.9 ± 0.8 | 0.9 ± 0.8 | 1.00 | |
Pre-study medications, n (%) | Analgesics# | 15 (75) | 14 (70) | 0.72 |
Steroid+ | 12 (60) | 13 (65) | 0.74 | |
DMARDs* | 9 (45) | 11 (55) | 0.52 |